Impact of Androgen Deprivation Therapy on Physical and Cognitive Function, as Well as Quality of Life of Patients With Nonmetastatic Prostate Cancer

Journal of Urology

Volumn 176, Issue 6, 2006, Pages 2443-2447

  Joly, F ^a,b   Alibhai, S M H ^a   Galica, J ^a   Park, A ^a   Yi, Q L ^a   Wagner, L ^c   Tannock, I F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FRANÇOIS BACLESSE   (France)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cognition; neoplasm metastasis; prostatic neoplasms; quality of life

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; ENERGY; FATIGUE; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SELF REPORT; SEXUAL FUNCTION; WALKING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; COGNITION; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; PHYSICAL FITNESS; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 33750505645     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.151     Document Type: Article

References (21)

1. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103
2. Holzbeierlein J.M., McLaughlin M.D., and Thrasher J.B. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 14 (2004) 177
3. Green H.J., Pakenham K.I., Headley B.C., Yaxley J., Nicol D.L., Mactaggart P.N., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90 (2002) 427
4. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 (2003) 1808
5. Salminen E., Portin R., Korpela J., Backman H., Parvinen L.M., Helienus H., et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 89 (2003) 971
6. Jenkins V.A., Bloomfield D.J., Shilling V.M., and Edginton T.L. Does neoadjuvant hormone therapy for early prostate cancer affect cognition?. Results from a pilot study. BJU Int 96 (2005) 48
7. Butland R.J., Pang J., Gross E.R., Woodcock A.A., and Geddes D.M. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J 284 (1982) 1607
8. Mathiowetz V., Kashman N., Volland G., Weber K., Dowe M., and Roger S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil 66 (1985) 69
9. Podsiadlo D., and Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriat Soc 39 (1991) 142
10. Lawton M.P., and Brody E.M. Assessment of older people: self-maintaining and instrument activities of daily living. Gerontologist 9 (1969) 179
11. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154
12. Cella D., Eton D.T., Lai J.S., Peterman A.H., and Merkel D.E. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24 (2002) 547
13. Wagner L.I., Sweet J., Cella D., and Doninger N. Chemotherapy-related cognitive deficits: a qualitative examination of patients and providers. Ann Behav Med 25 (2003) S056
14. Ritvo P., Irvine J., Naglie G., Tomlinson G., Bzjak A., Matthew A., et al. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. J Clin Epidemiol 58 (2005) 466
15. Montorio I., and Izal M. The geriatric depression scale: a review of its development and utility. Int Psychogeriatr 8 (1996) 103
16. Fogel B.S. The high sensitivity cognitive screen. Int Psychogeriatr 3 (1991) 273
17. Tchen N., Juffs H.G., Downie F.P., Yi Q.L., Hu H., Chemerynsky I., et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. A prospective matched cohort study. J Clin Oncol 21 (2003) 4175
18. Green H., Pakenham K., Headley B., Yaxley J., Nicol D.L., Mactaggart P.N., et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate carcinoma: a randomized controlled trial. BJU Int 93 (2004) 975
19. Salminen E.K., Portin R.I., Koskinen A.I., Helienus H.Y., and Nurmi M.J. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 11 (2005) 2956
20. Chen A.C., and Petrylak D.P. Complications of androgen-deprivation therapy in men with prostate cancer. Curr Urol Rep 6 (2005) 210
21. Descazeaud A., Chaskalovic J., Debre B., Zerbib M., and Peyromaure M. Sexual function after radical prostatectomy does not affect global patient satisfaction. Prog Urol 14 (2004) 1177